Latest News & Updates

Breaking News

  • 7 minutes ago

  • Pharma Now Editorial Team

Idorsia Achieves Sustained Albuminuria Reductions with Aprocitentan in Phase 3 PRECISION Renal Analysis
Breaking News
Roche Advances Enicepatide and Petrelintide Into Phase III While Initiating Combination Trial at ADA 2026

Pharma Now Editorial Team

Other trending news you may like to read

Idorsia Achieves Sustained Albuminuria Reductions with Aprocitentan in Phase 3 PRECISION Renal Analysis

Idorsia's Phase 3 PRECISION data show aprocitentan cuts albuminuria significantly through Week 36, strengthening the renal evidence base for potential label expansion.

Pharma Now Editorial Team

Pharma Now

Roche Advances Enicepatide and Petrelintide Into Phase III While Initiating Combination Trial at ADA 2026

Roche advances enicepatide and petrelintide to Phase III and launches a combination trial, signalling significant CMC and manufacturing scale-up ahead.

Pharma Now Editorial Team

Pharma Now

Idorsia Achieves High-Dose Immunogenicity Milestone in Phase 1 C. difficile Synthetic Glycan Vaccine Program

Idorsia's Phase 1 high-dose cohort confirms dose-dependent IgG immunogenicity for its synthetic glycan C. difficile vaccine, with partnership and scale-up next.

Pharma Now Editorial Team

Pharma Now

Novartis Presents 31 Immunology Abstracts at EULAR 2026 Spanning Biologics and CAR-T Modalities

Novartis presents 31 EULAR 2026 abstracts spanning secukinumab, ianalumab, and CAR-T rap-cel across multiple autoimmune indications.

Pharma Now Editorial Team

Pharma Now